MarketsandMarkets: BRIC Diabetes Drugs Market Worth US$8.7 Billion By 2014

DALLAS, Texas, April 20, 2010 - The report on BRIC Diabetes Drugs Market
(www.marketsandmarkets.com/Market-Reports/bric-diabetes-199.html)
analyzes the market for oral drugs and injectables in BRIC economies over the
period 2009 to 2014. The report measures and forecasts the BRIC market for
diabetes drugs; and analyzes the major market drivers, restraints, and
opportunities.

Browse more than 15 market data tables and in-depth TOC on BRIC Diabetes
Drugs Market. Early buyers will receive 10% customization of reports.

www.marketsandmarkets.com/Market-Reports/bric-diabetes-199.html

The BRIC diabetes drugs market is expected to grow from $3.9 billion in
2009 to reach $8.7 billion by 2014, growing at a CAGR of 17.1% from 2009 to
2014. Oral drugs accounted for around 65% of the market in 2009, but
injectables are expected to have a higher CAGR of 21.9%.

The slowdown of the pharma market growth in developed economies has
concentrated investor interest on BRIC nations, where the diabetes drug
market has benefitted significantly from government initiatives for spreading
patient awareness, and the subsequent increase in the uptake of novel drugs
such as incretin mimetics (Eli Lilly's Byetta) and dipeptidyl inhibitors
(Merck's Januvia and Novartis' Galvus).

SCOPE AND FORMAT

The report analyzes the BRIC Diabetes Drugs market into the following
segments:

    - Injectables Market: (Insulin, exenatide)
    - Oral Drugs Market: (Metformin, sulfonylureas, thaizolidinediones,
      dipeptidyl inhibitors, meglitinides, alpha glucosidase inhibitors,
      combination medications)

In addition to market tables for each submarket, each section of the
report will provide market trends, drivers, and opportunities. The report
also draws a competitive landscape, profiling the key players and the
top-selling products in the diabetes drug market in BRIC.

Analyst Briefing Presentation on the BRIC Diabetes Drugs Market to be
held on 4th May 2010

The Healthcare practice at MarketsandMarkets is pleased to announce its
Analyst Briefing Presentation on the BRIC Diabetes Drugs Market to be held on
4th May 2010. This analyst briefing focuses on the BRIC diabetes drugs market
over the period 2009 to 2014. The agenda for the briefing includes a
discussion on key high-growth markets, identifying the growth trends in
products and services. The briefing will also cover the market's competitive
scenario and trends and opportunities in the macro- and micro-markets of
Brazil, Russia, India, and China.

To register your participation, please click here.
www.marketsandmarkets.com/AnalystBriefing/BRIC-Diabetes-Drugs.asp

About MarketsandMarkets

MarketsandMarkets (M&M) is a global market research and consulting
company based in the U.S. We publish strategically analyzed market research
reports and serve as a business intelligence partner to Fortune 500 companies
across the world. MarketsandMarkets also provides multi-client reports,
company profiles, databases, and custom research services.

M&M covers thirteen industry verticals, including advanced materials,
automotive and transportation, banking and financial services, biotechnology,
chemicals, consumer goods energy and power, food and beverages, industrial
automation, medical devices, pharmaceuticals, semiconductor and electronics,
and telecommunications and IT. Browse all our titles at
www.marketsandmarkets.com.

    Contact:
    Ms. Sunita
    108, West 13th Street
    Wilmington, DE, 19801
    County of New Castle
    Tel: +1-888-989-8004
    Email: sales@marketsandmarkets.com

Contact: Ms. Sunita, 108, West 13th Street, Wilmington, DE, 19801, County of New Castle, Tel: +1-888-989-8004, Email: sales at marketsandmarkets.com